Get the latest market trends in your inbox

Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Epidiolex has a list price of $1,310 per bottle. Photo: GW Pharmaceuticals

Sales of the epilepsy drug Epidiolex hit almost $300 million in 2019, GW Pharmaceuticals reported Tuesday. Sales are expected to surpass a half-billion dollars this year as the drug gains more insurance coverage in Europe.

Why it matters: Epidiolex is the first FDA-approved medication made from a substance in cannabis, and it's starting to take off.

Where things stand: Epidiolex got off the ground in 2018, and more doctors started to prescribe the medicine in 2019. Roughly 60% of patients taking Epidiolex are kids who suffer from rare diseases that cause seizures.

  • New launches in Germany, the U.K., France, Spain and Italy will help almost double Epidiolex sales this year, according to Wall Street analysts.
  • It also doesn't hurt that GW Pharmaceuticals raised the list price of Epidiolex by 6% this past January, from $1,235 per 100 mL bottle to $1,310 — even though nothing about the drug changed.

Go deeper: Pharma starting to see green with cannabis

Go deeper

Obama: Broad slogans like "defund the police" lose people

Snapchat.

Former President Barack Obama told Peter Hamby on the Snapchat original political show "Good Luck America" that "snappy" slogans such as "defund the police" can alienate people, making the statements less effective than intended.

What he's saying: "You lost a big audience the minute you say it, which makes it a lot less likely that you're actually going to get the changes you want done," Obama told Hamby in an interview that will air Wednesday morning at 6 a.m. EST on Snapchat.

Nasdaq's ultimatum

Photo: Kelly Sullivan/Getty Images

New diversity and inclusion rules are on the table for some of America's most powerful corporations, courtesy of one of its most powerful stock exchanges.

What's new: Nasdaq is threatening to delist companies that won't move toward having at least one woman and at least one underrepresented minority or LGBTQ person on their corporate boards.

Erica Pandey, author of @Work
2 hours ago - Economy & Business

The broken pipeline for Latino executives

Illustration: Annelise Capossela/Axios

Latino professionals have the widest gap between representation in the labor force and executive positions — bigger than that of any other minority group.

Why it matters: Latinos will make up a quarter of the U.S. population by 2050, and scores of U.S. firms profit off of Latino consumers, but this group is absent from the business world's highest and most impactful decision-making positions.